GlassScriptPhysician profile
Matthew Grady Macdougall
NPI 1053638320
$3,522.11
in general payments reported to CMS, 2019-2025
21 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $1,976 · 2021: $130 · 2022: $42.68 · 2024: $576 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,888.44 | 2020 | |
| Boston Scientific Corporation | $725.75 | 2019-2025 | Vercise, General - Dbs, Suretek |
| Medtronic, INC. | $132.44 | 2022-2024 | Percept PC Brainsense |
| Medtronic USA, INC. | $103.57 | 2019-2020 | |
| Abbott Laboratories | $91.02 | 2020-2024 | Infinity |
| Globus Medical, INC. | $77.69 | 2024 | Excelsiusgps Robotic Navigation System, Altera |
| Novartis Pharmaceuticals Corporation | $62.72 | 2019 | |
| Livanova USA, INC. | $60.67 | 2019 | |
| Alphatec Spine, INC | $56.13 | 2021 | |
| Neuropace, INC. | $50.57 | 2024 | |
| Nuvasive, INC. | $44.62 | 2021-2022 | |
| Bausch Health US, LLC | $34.55 | 2019 | |
| Nevro Corp. | $26.91 | 2024 | Senza |
| Neurocrine Biosciences, INC. | $26.72 | 2019 | |
| Adamas Pharmaceuticals, INC. | $24.92 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aesculap, INC. | $24.33 | 2021 | |
| Ucb, INC. | $22.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.77 | 2021 | |
| Avanir Pharmaceuticals, INC. | $20.58 | 2019 | |
| Greenwich Biosciences, INC. | $15.60 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Macdougall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.